Combined impact of hypoalbuminemia and pharmacogenomic variants on voriconazole trough concentration: data from a real-life clinical setting in the Chinese population

References

• Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database. Clin Infect Dis. 2010;50(8):1091–1100. doi: 10.1086/651263.
   PubMed Web of Science ®Google Scholar
• Hoenigl M, Salzer HJF, Raggam RB, et al. Impact of galactomannan testing on the prevalence of invasive aspergillosis in patients with hematological malignancies. Med Mycol. 2012;50(3):266–269. doi: 10.3109/13693786.2011.603102.
   PubMed Web of Science ®Google Scholar
• Jeu L, Piacenti FJ, Lyakhovetskiy AG, et al. Voriconazole. Clin Ther. 2003;25(5):1321–1381. doi: 10.1016/s0149-2918(03)80126-1.
   PubMed Web of Science ®Google Scholar
• Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet. 2006;45(7):649–663. doi: 10.2165/00003088-200645070-00002.
   PubMed Web of Science ®Google Scholar
• Jin H, Wang T, Falcione BA, et al. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis. J Antimicrob Chemother. 2016;71(7):1772–1785. doi: 10.1093/jac/dkw045.
   PubMed Web of Science ®Google Scholar
• Allegra S, De Francia S, De Nicolo A, et al. Effect of gender and age on voriconazole trough concentrations in Italian adult patients. Eur J Drug Metab Pharmacokinet. 2020;45(3):405–412. doi: 10.1007/s13318-019-00603-6.
   PubMed Web of Science ®Google Scholar
• Chen C, Yang T, Li X, et al. Population pharmacokinetics of voriconazole in Chinese patients with hematopoietic stem cell transplantation. Eur J Drug Metab Pharmacokinet. 2019;44(5):659–668. doi: 10.1007/s13318-019-00556-w.
   PubMed Web of Science ®Google Scholar
• Wei X, Zhao M, Fu P, et al. Risk factors associated with insufficient and potentially toxic voriconazole plasma concentrations: an observational study. J Chemother. 2019;31(7–8):401–407. doi: 10.1080/1120009X.2019.1646974.
   PubMed Web of Science ®Google Scholar
• Blanco-Dorado S, Cea-Arestin C, Gonzalez Carballo A, et al. An observational study of the efficacy and safety of voriconazole in a real-life clinical setting. J Chemother. 2019;31(1):49–57. doi: 10.1080/1120009X.2018.1524085.
   PubMed Web of Science ®Google Scholar
• Vaisman N, Clarke R, Rossi M, et al. Protein turnover and resting energy expenditure in patients with undernutrition and chronic lung disease. Am J Clin Nutr. 1992;55(1):63–69. doi: 10.1093/ajcn/55.1.63.
   PubMed Web of Science ®Google Scholar
• Neyra R, Chen KY, Sun M, et al. Increased resting energy expenditure in patients with end-stage renal disease. JPEN J Parenter Enteral Nutr. 2003;27(1):36–42. doi: 10.1177/014860710302700136.
   PubMed Web of Science ®Google Scholar
• Ñamendys-Silva SA, González-Herrera MO, Texcocano-Becerra J, et al. Hypoalbuminemia in critically ill patients with cancer: incidence and mortality. Am J Hosp Palliat Care. 2011;28(4):253–257. doi: 10.1177/1049909110384841.
   PubMed Web of Science ®Google Scholar
• Deluche E, Girault S, Jesus P, et al. Assessment of the nutritional status of adult patients with acute myeloid leukemia during induction chemotherapy. Nutrition. 2017;41:120–125. doi: 10.1016/j.nut.2017.04.011.
   PubMed Web of Science ®Google Scholar
• Dote S, Sawai M, Nozaki A, et al. A retrospective analysis of patient-specific factors on voriconazole clearance. J Pharm Health Care Sci. 2016;2:10. doi: 10.1186/s40780-016-0044-9.
   PubMed Web of Science ®Google Scholar
• Chantharit P, Tantasawat M, Kasai H, et al. Population pharmacokinetics of voriconazole in patients with invasive aspergillosis: serum albumin level as a novel marker for clearance and dosage optimization. Ther Drug Monit. 2020;42(6):872–879. doi: 10.1097/FTD.0000000000000799.
   PubMed Web of Science ®Google Scholar
• Khan-Asa B, Punyawudho B, Singkham N, et al. Impact of albumin and omeprazole on Steady-State population pharmacokinetics of voriconazole and development of a voriconazole dosing optimization model in thai patients with hematologic diseases. Antibiotics. 2020;9(9):E574. doi: 10.3390/antibiotics9090574.
   Google Scholar
• Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos. 2003;31(5):540–547. doi: 10.1124/dmd.31.5.540.
   PubMed Web of Science ®Google Scholar
• Scholz I, Oberwittler H, Riedel KD, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol. 2009;68(6):906–915. doi: 10.1111/j.1365-2125.2009.03534.x.
   PubMed Web of Science ®Google Scholar
• Zhong X, Tong X, Ju Y, et al. Interpersonal factors in the pharmacokinetics and pharmacodynamics of voriconazole: are CYP2C19 genotypes enough for Us to make a clinical decision? Curr Drug Metab. 2018;19(14):1152–1158. doi: 10.2174/1389200219666171227200547.
   PubMed Web of Science ®Google Scholar
• Mangal N, Hamadeh IS, Arwood MJ, et al. Optimization of voriconazole therapy for the treatment of invasive fungal infections in adults. Clin Pharmacol Ther. 2018;104(5):957–965. doi: 10.1002/cpt.1012.
   PubMed Web of Science ®Google Scholar
• Zeng G, Shi L, Li H, et al. Effect of cyclosporine a and polymorphisms in CYP2C19 and ABCC2 on the concentration of voriconazole in patients undergoing allogeneic hematopoietic stem cell transplantation. Xenobiotica. 2020;50(5):614–619. doi: 10.1080/00498254.2019.1672907.
   PubMed Web of Science ®Google Scholar
• Interaction of serum proteins with CYP isoforms in human liver microsomes: inhibitory effects of human and bovine albumin, alpha-globulins, alpha-1-acid glycoproteins and gamma-globulins on CYP2C19 and CYP2D6. Life Sci. 2003;72(17):1953–1962.
   PubMed Web of Science ®Google Scholar
• Kandel SE, Lampe JN. Role of protein-protein interactions in cytochrome P450-mediated drug metabolism and toxicity. Chem Res Toxicol. 2014;27(9):1474–1486. doi: 10.1021/tx500203s.
   PubMed Web of Science ®Google Scholar
• Shao B, Ma Y, Li Q, et al. Effects of cytochrome P450 3A4 and non-genetic factors on initial voriconazole serum trough concentrations in hematological patients with different cytochrome P450 2C19 genotypes. Xenobiotica. 2017;47(12):1121–1129. doi: 10.1080/00498254.2016.1271960.
   PubMed Web of Science ®Google Scholar
• Chuwongwattana S, Jantararoungtong T, Prommas S, et al. Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in thai patients with invasive fungal infections. Pharmacol Res Perspect. 2020;8(6):e00665. doi: 10.1002/prp2.665.
   PubMed Web of Science ®Google Scholar
• He HR, Sun JY, Ren XD, et al. Effects of CYP3A4 polymorphisms on the plasma concentration of voriconazole. Eur J Clin Microbiol Infect Dis. 2015;34(4):811–819. doi: 10.1007/s10096-014-2294-5.
   PubMed Web of Science ®Google Scholar
• Yanni SB, Annaert PP, Augustijns P, et al. Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes. Drug Metab Dispos. 2008;36(6):1119–1125. doi: 10.1124/dmd.107.019646.
   PubMed Web of Science ®Google Scholar
• Allegra S, Fatiguso G, Francia SD, et al. Pharmacogenetic of voriconazole antifungal agent in pediatric patients. Pharmacogenomics. 2018;19(11):913–925. doi: 10.2217/pgs-2017-0173.
   PubMed Web of Science ®Google Scholar
• Dapía I, García I, Martinez JC, et al. Prediction models for voriconazole pharmacokinetics based on pharmacogenetics: an exploratory study in a spanish population. Int J Antimicrob Agents. 2019;54(4):463–470. doi: 10.1016/j.ijantimicag.2019.06.026.
   PubMed Web of Science ®Google Scholar
• Zeng G, Wang L, Shi L, et al. Variability of voriconazole concentrations in patients with hematopoietic stem cell transplantation and hematological malignancies: influence of loading dose, procalcitonin, and pregnane X receptor polymorphisms. Eur J Clin Pharmacol. 2020;76(4):515–523. doi: 10.1007/s00228-020-02831-1.
   PubMed Web of Science ®Google Scholar
• Aiuchi N, Nakagawa J, Sakuraba H, et al. Impact of polymorphisms of pharmacokinetics-related genes and the inflammatory response on the metabolism of voriconazole. Pharmacol Res Perspect. 2022;10(2):e00935.
   PubMed Web of Science ®Google Scholar
• Mitsani D, Nguyen MH, Shields RK, et al. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. Antimicrob Agents Chemother. 2012;56(5):2371–2377. doi: 10.1128/AAC.05219-11.
   PubMed Web of Science ®Google Scholar
• Myrianthefs P, Markantonis SL, Evaggelopoulou P, et al. Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study. Int J Antimicrob Agents. 2010;35(5):468–472. doi: 10.1016/j.ijantimicag.2009.12.021.
   PubMed Web of Science ®Google Scholar
• Kim SH, Kwon JC, Park C, et al. Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether β-cyclodextrin in haematological patients with renal impairment. Mycoses. 2016;59(10):644–651. doi: 10.1111/myc.12517.
   PubMed Web of Science ®Google Scholar
• van Wanrooy MJP, Span LFR, Rodgers MGG, et al. Inflammation is associated with voriconazole trough concentrations. Antimicrob Agents Chemother. 2014;58(12):7098–7101. doi: 10.1128/AAC.03820-14.
   PubMed Web of Science ®Google Scholar
• Trifilio SM, Yarnold PR, Scheetz MH, et al. Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation. Antimicrob Agents Chemother. 2009;53(5):1793–1796. doi: 10.1128/AAC.01316-08.
   PubMed Web of Science ®Google Scholar
• Luong ML, Al-Dabbagh M, Groll AH, et al. Utility of voriconazole therapeutic drug monitoring: a meta-analysis. J Antimicrob Chemother. 2016;71(7):1786–1799. doi: 10.1093/jac/dkw099.
   PubMed Web of Science ®Google Scholar
• Gounden V, Vashisht R, Jialal I. Hypoalbuminemia. In: StatPearls. [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Jun 19]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK526080/
   Google Scholar
• Xin X, Huang H, Lu W, et al. Albumin concentration is a candidate indicator for predicting the risk of calf venous thromboembolism in patients undergoing gynecologic surgery. Int J Gynaecol Obstet. 2022;156(1):139–144. doi: 10.1002/ijgo.13675.
   PubMed Web of Science ®Google Scholar
• Montomoli J, Erichsen R, Antonsen S, et al. Impact of preoperative serum albumin on 30-day mortality following surgery for colorectal cancer: a population-based cohort study. BMJ Open Gastroenterol. 2015;2(1):e000047. doi: 10.1136/bmjgast-2015-000047.
   PubMedGoogle Scholar
• Gautier-Veyret E, Thiebaut-Bertrand A, Roustit M, et al. Optimization of voriconazole therapy for treatment of invasive aspergillosis: pharmacogenomics and inflammatory status need to be evaluated. Br J Clin Pharmacol. 2021;87(6):2534–2541. doi: 10.1111/bcp.14661.
   PubMed Web of Science ®Google Scholar
• Veringa A, ter Avest M, Span LFR, et al. Voriconazole metabolism is influenced by severe inflammation: a prospective study. J Antimicrob Chemother. 2017;72(1):261–267. doi: 10.1093/jac/dkw349.
   PubMed Web of Science ®Google Scholar
• Luo X, Li T, Hu L, et al. Differential effects of C-reactive protein levels on voriconazole metabolism at three age groups in allogeneic hematopoietic cell transplant recipients. J Chemother. 2021;33(2):95–105. doi: 10.1080/1120009X.2020.1765604.
   PubMed Web of Science ®Google Scholar
• Naito T, Yamada T, Mino Y, et al. Impact of inflammation and concomitant glucocorticoid administration on plasma concentration of triazole antifungals in immunocompromised patients. Clin Chim Acta. 2015;441:127–132. doi: 10.1016/j.cca.2014.12.024.
   PubMed Web of Science ®Google Scholar
• Bologa RM, Levine DM, Parker TS, et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis. 1998;32(1):107–114. doi: 10.1053/ajkd.1998.v32.pm9669431.
   PubMed Web of Science ®Google Scholar
• Morgan ET, Goralski KB, Piquette-Miller M, et al. , Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos. 2008;36(2):205–216. doi: 10.1124/dmd.107.018747.
   PubMed Web of Science ®Google Scholar
• Cheng L, Xiang R, Liu F, et al. Therapeutic drug monitoring and safety of voriconazole in elderly patients. Int Immunopharmacol. 2020;78:106078. doi: 10.1016/j.intimp.2019.106078.
   PubMed Web of Science ®Google Scholar
• Vanstraelen K, Wauters J, Vercammen I, et al. Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients. Antimicrob Agents Chemother. 2014;58(11):6782–6789. doi: 10.1128/AAC.03641-14.
   PubMed Web of Science ®Google Scholar
• Weiss JS, Gautam A, Lauff JJ, et al. The clinical importance of a protein-bound fraction of serum bilirubin in patients with hyperbilirubinemia. N Engl J Med. 1983;309(3):147–150. doi: 10.1056/NEJM198307213090305.
   PubMed Web of Science ®Google Scholar